menu
    • menu

    Company profile for Dyne Therapeutics

    NEW Drugs in Dev: 4
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Dyne was founded with a singular focus: to transform the lives of people with serious muscle diseases by pioneering muscle-targeted therapies. Our proprietary technologies provide the foundation for breakthrough treatments. We have assembled a world-class team of experts who are united by their commitment to fulfill this mission.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dyne TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Technology Square 10th Floor Cambridge, MA, 02139
    Telephone
    Telephone
    (508) 277-8117
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dyne-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/dynetx
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/dyne_tx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dyne Announces FORCE CNS Activity in Primates at ASGCT 2026
    Dyne Announces FORCE CNS Activity in Primates at ASGCT 2026

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3282066/0/en/dyne-therapeutics-announces-upcoming-presentation-highlighting-robust-cns-activity-in-nonhuman-primates-with-its-force-platform-at-2026-asgct-annual-meeting.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Rules
    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Rules

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3280362/0/en/dyne-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Dyne To Present At AMCP 2026 For Neuromuscular Portfolio
    Dyne To Present At AMCP 2026 For Neuromuscular Portfolio

    01 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/01/3266512/0/en/Dyne-Therapeutics-Announces-Participation-at-2026-Academy-of-Managed-Care-Pharmacy-AMCP-Conference-to-Begin-Shaping-Access-in-US-for-Potential-Neuromuscular-Medicines.html

    GLOBENEWSWIRE
    01 Apr 2026
    Share Share
    Dyne To Pursue FDA Approval Following Positive Long-Term Data
    Dyne To Pursue FDA Approval Following Positive Long-Term Data

    10 Mar 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/dyne-plans-post-prasad-fda-run-as-duchenne-exon-skipper-sustains-benefit-in-long-term-data

    BIOSPACE
    10 Mar 2026
    Share Share
    Dyne Therapeutics Unveils 2025 Financials And Business Updates
    Dyne Therapeutics Unveils 2025 Financials And Business Updates

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247269/0/en/Dyne-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Business-Highlights.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Dyne Therapeutics To Participate In Upcoming Investor Conferences
    Dyne Therapeutics To Participate In Upcoming Investor Conferences

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244510/0/en/Dyne-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search